Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Free Cash Flow (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported Free Cash Flow over the past 16 years, most recently at $3.2 million for Q2 2025.

  • Quarterly results put Free Cash Flow at $3.2 million for Q2 2025, down 45.86% from a year ago — trailing twelve months through May 2025 was -$13.6 million (up 24.9% YoY), and the annual figure for FY2025 was -$13.6 million, up 24.9%.
  • Free Cash Flow for Q2 2025 was $3.2 million at Lifecore Biomedical, Inc. \De\, up from -$4.3 million in the prior quarter.
  • Over the last five years, Free Cash Flow for LFCR hit a ceiling of $15.7 million in Q2 2022 and a floor of -$36.0 million in Q1 2022.
  • Median Free Cash Flow over the past 5 years was -$4.1 million (2024), compared with a mean of -$5.7 million.
  • Peak annual rise in Free Cash Flow hit 959.33% in 2022, while the deepest fall reached 625.53% in 2022.
  • Lifecore Biomedical, Inc. \De\'s Free Cash Flow stood at -$3.9 million in 2021, then skyrocketed by 56.85% to -$1.7 million in 2022, then plummeted by 94.21% to -$3.3 million in 2023, then plummeted by 161.11% to -$8.6 million in 2024, then skyrocketed by 137.88% to $3.2 million in 2025.
  • The last three reported values for Free Cash Flow were $3.2 million (Q2 2025), -$4.3 million (Q1 2025), and -$8.6 million (Q4 2024) per Business Quant data.